Last reviewed · How we verify

Relistor Injectable Product

Methodist Health System · Phase 2 active Small molecule

Relistor Injectable Product is a Small molecule drug developed by Methodist Health System. It is currently in Phase 2 development. Also known as: Methylnaltrexone Bromide.

At a glance

Generic nameRelistor Injectable Product
Also known asMethylnaltrexone Bromide
SponsorMethodist Health System
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Relistor Injectable Product

What is Relistor Injectable Product?

Relistor Injectable Product is a Small molecule drug developed by Methodist Health System.

Who makes Relistor Injectable Product?

Relistor Injectable Product is developed by Methodist Health System (see full Methodist Health System pipeline at /company/methodist-health-system).

Is Relistor Injectable Product also known as anything else?

Relistor Injectable Product is also known as Methylnaltrexone Bromide.

What development phase is Relistor Injectable Product in?

Relistor Injectable Product is in Phase 2.

Related